Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Inclusion Criteria: * Age ≥18 years * ECOG Performance Status ≤ 1. * Estimated life expectancy of at least 12-weeks; * Measurable disease as per RECIST guideline (Version 1.1); Exclusion Criteria: * Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer * Known hypersensitivity to the study drugs * Treatment with any anti-cancer agents within 28 days of study entry * Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy